Key Points
- Insider David Malcom Rodman sold 2,171 shares on Feb. 9 at $30.21 for $65,585.91, cutting his stake to 50,437 shares (a 4.13% decrease) valued at about $1.52M.
- Rodman has conducted multiple large sales in January (notably 192,715 shares on Jan. 5 and 70,037 shares on Jan. 2), indicating sustained insider selling worth several million dollars.
- Mineralys (NASDAQ:MLYS) has a market cap of ~$2.36B, a one‑year range of $8.24–$47.65, ~84.5% institutional ownership, and a consensus analyst rating of "Moderate Buy" with an average target of $47.43.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,171 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $30.21, for a total transaction of $65,585.91. Following the completion of the sale, the insider owned 50,437 shares of the company's stock, valued at $1,523,701.77. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
David Malcom Rodman also recently made the following trade(s):
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total transaction of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total value of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total value of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total value of $6,748,879.30.
Mineralys Therapeutics Stock Performance
Mineralys Therapeutics stock opened at $29.78 on Thursday. The company has a market cap of $2.36 billion, a P/E ratio of -10.09 and a beta of 0.51. Mineralys Therapeutics, Inc. has a one year low of $8.24 and a one year high of $47.65. The business has a fifty day moving average of $34.33 and a two-hundred day moving average of $33.35.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. Sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Institutional Investors Weigh In On Mineralys Therapeutics
A number of large investors have recently bought and sold shares of MLYS. Navalign LLC purchased a new position in Mineralys Therapeutics during the fourth quarter worth $33,000. Smartleaf Asset Management LLC increased its position in Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock worth $40,000 after purchasing an additional 676 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock worth $54,000 after purchasing an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Mineralys Therapeutics in the 2nd quarter valued at about $91,000. Finally, Russell Investments Group Ltd. lifted its holdings in Mineralys Therapeutics by 14,091.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock valued at $124,000 after purchasing an additional 3,241 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on MLYS shares. Wells Fargo & Company lifted their price target on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. HC Wainwright boosted their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday, November 12th. Finally, Stifel Nicolaus raised their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $47.43.
View Our Latest Report on Mineralys Therapeutics
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
